

January 2026

MODULATING IMMUNE RESPONSE THROUGH ADVANCED CELL THERAPEUTICS

(RESTEM

Disclosures

This presentation has been prepared for use by RESTEM GROUP INC. and its affiliates (“RESTEM”). This presentation, and any information disclosed, whether in writing or orally, as part of, or otherwise in connection with this presentation, is for information purposes only and is being provided to you solely in your capacity to consider any RESTEM operations, financials, and clinical studies, among other areas. The presentation may not be used for any other purpose and may not be reproduced or redistributed, in whole or in part, without the prior written consent of RESTEM.

Any photocopying, disclosure, reproduction, or alteration of the contents of this presentation and any forwarding of a copy of this presentation or any portion of this presentation to any person is prohibited. This presentation is not intended to be all-inclusive or to contain all the information that a person may desire in considering an investment in RESTEM and is not intended to form the basis of any investment decision in RESTEM. You should consult your own legal, regulatory, tax, business, financial and accounting advisors to the extent you deem necessary and must make your own investment decision and perform your own independent investigation and analysis of an investment in RESTEM and the transactions contemplated in this presentation.

This presentation shall neither constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. Neither the Securities and Exchange Commission nor any state or territorial securities commission has approved or disapproved of the securities or determined if this presentation is truthful or complete.

This Presentation contains information that constitutes “forward-looking statements,” which can be identified by the use of forward-looking terminology such as “may,” “can,” “will,” “could,” “expect,” “project,” “estimate,” “potential,” “intend,” or “believe” or the negatives thereof or other comparable terminology. Due to various risks and uncertainties, actual events or results or the actual performance of new investments may differ materially from those reflected or contemplated in such forward-looking statements. Nothing contained herein should be deemed to be a prediction or projection of the future performance. Nothing contained in this Presentation is designed to create a financial advisory or other relationship with any prospective investor or any other party and the creation of any such relationship is expressly disclaimed.

There can be no assurance that any targeted returns or other financial, operational, or strategic results will be met or that RESTEM will be able to implement its business strategy and clinical approach or achieve its investment objective. Actual returns will depend on, among other factors, general economic conditions, market conditions, one-time events, and other factors that will be described in the definitive offering documents. All investments involve risk, including possible loss of principal.

Company Overview

Private



Founded in 2018, the company has established a strong foundation in the **field of cell-based therapeutics** and developed a **robust patent portfolio**

Multi-asset



3 proprietary platforms, with the common focus of **modulating the immune system** and treating **inflammatory-associated diseases**

Late-stage



Commencing in 2026 **pivotal Phase 2/3 trials** in Idiopathic Inflammatory Myopathy (**IIM**) and refractory Rheumatoid Arthritis (**RA**). Successfully completed multiple INDs and eINDs across **11 different indications**, demonstrating initial **clinical benefits** and an excellent **safety profile**.

Competitive Advantages



Breaking through the key limitations of cell therapeutics with **cost-effective manufacturing, enhanced scalability** and **minimized toxicity**.

Platform Overview

Restem-L *Autoimmunity*

Umbilical-lining Modified Progenitor Cell (UMPC) product, developed using a **patented conditioning process**, to target **key inflammatory pathways** in **autoimmune diseases**

Restem-X *Orthopedics*

Secretome-based product, **functionally optimized** to deliver ground-breaking therapeutic properties in **orthopedic** treatments

aNK *Immuno-senescence*

Activated natural killer (aNK) cells, uniquely designed to **reverse immuno-senescence** and combat **aging-related disorders**

Experienced Management Team & Advisory Board

Management Team



Andres Isaias

*Executive Chairman &
Chief Executive Officer*



Rafael Gonzalez, PhD

*Chief Development &
Scientific Officer*



Keith March, MD, PhD

Chief Medical Officer




Nelson Cabatuan

Chief Financial Officer



Barb Eppler-Mossler PhD

Sr. VP of Regulatory Affairs



Brian Pla

*Chief Business
Development Officer*

Scientific Advisory Board

Robert Sackstein, MD, PhD

SVP for Global Health Affairs,
Florida International University




Robert Negrin, MD, PhD

Division Chief, Blood and Marrow
Transplant Program, Medical
Director, Clinical Bone Marrow
Transplantation Laboratory



Guenther Koehne, MD, PhD

Deputy Director and Chief of
Blood & Marrow Transplant and
Hematologic Oncology



Jonathan Krant, MD

Chief of Rheumatology Division,
Memorial Health System, and
former Chairman of Medicine,
Adirondack Health Systems



Advancing Pipeline of Cell Therapeutics


	Program	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Status
UMPC	Restem-L: <i>Autoimmune Diseases</i>	Idiopathic Inflammatory Myopathy (IIM) * / **					Currently enrolling Phase 2/3 trial
		Rheumatoid Arthritis Refractory (ref-RA)					Received FDA IND Clearance; Phase 2/3 initiation in Q2 2026
		Ulcerative Colitis Refractory (ref-UC)					Received FDA IND Clearance; Phase 2 initiation in Q3 2026
	Restem-L: <i>Other Diseases</i>	Left Ventricular Assisted Device (LVAD)					Partnering Opportunity
		Facioscapulohumeral Muscular Dystrophy (FSHD)**					Phase 1/2a trial ongoing
	Restem-X: <i>Orthopedics</i>	Osteoarthritis (OA)					Phase 1/2 IND submission in Q2 2026
aNK	aNK: <i>Age-Associated Disorders</i>	Age-associated disorder					Phase 1 IND submission in Q4 2026

UMPC: Umbilical lining Modified Progenitor Cells; aNK: activated Natural Killer cells

* FDA Fast Track and Orphan Drug designations granted

** Fully Committed Funding

Significant Market Potential for Restem Clinical Platforms




1. Lifesci Consulting Market Analysis 2024. 2. Lifesci Consulting Osteoarthritis Market Sizing 2025. 3. Solve FSHD, McKinsey Market Analysis.

*Projected global peak revenue for osteoarthritis, ulcerative colitis, rheumatoid arthritis and adult idiopathic inflammatory myopathy is by 2035. Potential sales for FSHD are projected within 5 years of launch.


Restem-L – Best-In-Class Cellular Therapeutic Product

Higher Scalability




Exceptional proliferative ability yields greater growth and expansion of high-quality cells

Younger & More Robust Cells



Maintains longer telomeres throughout multiple passages ensures younger and more robust cells

Better Repair Mechanism



Higher telomerase activation in later passages supports a stronger DNA repair mechanism

Superior Properties than Other Cell-based Products

Restem-L – Overcoming the Quintessential Cell Therapeutics Manufacturing Challenges

Scalability	Cost	Time	Consistency	Inventory
Extensive supply, with 3 master and working cell banks with a capability to produce	Manufacturing costs are advantageous, with a production cost of just	Accelerated manufacturing timeline from master/working bank to final product	Highly reproducible and complete characterization uniformity among donors and cell lines	GMP cells in inventory ready for use in clinic trials, with quick turn-around
> 3 million doses	< \$2,200 per dose	Under 6 weeks	Superior lot-to-lot consistency	180 doses

Uniquely positioned to support clinical trials and mass commercialization of cell-based products

Addressing the Growing Need for Autoimmune Therapies

Increasing Prevalence



1 in 10

individuals globally is affected
with autoimmune diseases¹

Existing Market



\$150 billion/yr

Estimated autoimmune disease
yearly market across multiple
indications²

Current Treatments



↑ AEs


Currently approved treatments
are associated with frequent
and severe adverse events

1. Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol. 2023 Feb;80:102266.

2. www.einpresswire.com/article/495486226/autoimmune-disease-therapeutics-market-nears-150-billion-by-2025-market-is-witnessing-a-strong-presence-of-late-stage-pipeline-drugs


Restem-L Strongly Modulates the Inflammatory Response

Inflammation is the driving force of autoimmune tissue injury




Restem-L Modulates Lymphocyte and Monocyte Factor Secretion to Treat Disease

Restem-L - Strongly Reduced Inflammatory Responses of White Cells in Clinical Trials



Restem-L markedly suppresses TNF α , a strong mediator of inflammation

RESTEM-L: Multi-Factorial Suppression of Pro-Inflammatory Cytokines and Upregulation of Anti-Inflammatory Factors



Restem-L markedly suppresses multiple inflammatory biomarkers

Restem-L in Adult Idiopathic Inflammatory Myopathy (IIM)

An autoimmune disease, with Polymyositis/Dermatomyositis (PM/DM) as its primary subtypes



Prevalence

~ 58,000

People with IIM in the US
alone*



Cost per Patient

\$200,000+/yr

Intravenous Immunoglobulin
(IVIg) is the only approved
treatment and is commonly in
short supply



Unmet Medical Needs


Toxicity

Currently managed with long-
term use of steroids,
which have many serious
side effects

Restem-L: Phase 1 Trial Results in IIM


Selected as a Clinical Science Highlight at the EULAR 2025 Congress

Durable Improvement




- The Total Improvement Score (TIS) averaged for all participants is within 30-35% range; 20% is considered a meaningful improvement by the FDA and Key Opinion Leaders
- The overall improvement in various scales was seen concurrently with a reduction in 6 of the 7 participants of the Prednisone daily dose

Reduction of Required Prednisone Dose



- The average daily dose of Prednisone was tapered by more than 5.5 mg by managing clinician (*chronic use of as little as 2.5 mg daily leads to increased adverse side effects*)
- 7 out of the 9 participants used Prednisone daily
- 6 out of the 7 daily users of Prednisone had an average of ~50% decrease in their steroid use

Restem-L: IIM Trial Results | A Disease Paradigm Shift



Restem-L: Phase 2/3 IIMPACT in IIM - a Potentially Registrational Trial


Pivotal, Adaptive double-blinded, randomized, dose-repeating, crossover study

Inclusion Criteria

≥18 years old with diagnosis of PM/DM based on EULAR/ACR score and Active Disease;

Participants must be receiving stable treatment, with one or more oral immunosuppressant medications, HCQ, and/or corticosteroids

Treatment Arms



Endpoints

Total Improvement Score (TIS), from baseline and by comparison with placebo;

Pre-specified steroid step-down to solidify the finding of the concurrent efficacy and steroid reduction




Institution / Investigator:
Veterans Affairs Medical Center / Michael Bubbs, MD (Principal Investigator)

Interim results anticipated in 2H 2026




Restem-L in Facioscapulohumeral Muscular Dystrophy (FSHD)

Rare neuromuscular disease, characterized by immune cell infiltration and inflammation, causing weakness and wasting in muscles



FSHD – Phase 1 FDA-Authorized Trial

Double-blinded, randomized, dose-repeating, placebo-controlled, crossover study



Institution / Investigator:
Stanford Neuroscience Health Center / John Day, MD, PhD (Principal Investigator)

Restem-L in Rheumatoid Arthritis (RA)



RA is a chronic, autoimmune disease of unknown etiology that primarily affects synovial joints



Prevalence

~ 1,650,000

Diagnosed adult RA patients in 2024 in the US alone*



Cost per Patient

\$80,000-\$120,000

Yearly cost of biologics which accounts for approximately 60% of RA patients



Unmet Medical Needs

~21%

Uncontrolled or refractory patient population**


*Note: Average volume of diagnosed RA cases was calculated for sources reporting a range of diagnosed prevalence rates : [Hunter, et al](#), [Myasoedova, et al](#), [Almutairi, et al](#)

** www.arthritis.org/news/stories-of-yes/dr-daniel-solomon-researching-refractory-ra.

*** Source: LifeSci Consulting market analysis, 2024

Restem-L: Phase 2/3 Trial in Rheumatoid Arthritis (RA)

Adaptive double-blinded, randomized, dose-repeating, parallel-group study




Institution / Investigator:
University of Florida / Michael Bubb, MD (Principal Investigator)



Restem-L in Ulcerative Colitis (UC)



UC is a chronic, inflammatory autoimmune condition characterized by relapsing and remitting mucosal inflammation




* Average volume of diagnosed UC cases was calculated for sources reporting a range of diagnosed prevalence rates : [Lewis, et al](#), [Weisman, et al](#), [Shivashankar, et al](#), [Kappelman, et al](#)
SoC- standard of care

** https://journals.lww.com/ajg/fulltext/2019/03000/acg_clinical_guideline_ulcerative_colitis_in.10.aspx?xd_co_f=M2QwOGlwMDItM2NhNC00MWQ2LThiNWYtYzMzNzlwOWVmM2U4~

*** Source: LifeSci Consulting market analysis, 2024


eIND UC Patient Data



Treatment with Restem-L led to prolonged remission and significant symptomatic improvement, whereas infiximab showed no association with symptom relief.

eIND UC Patient Data (Compounding Effect)


Irritable Bowel Syndrome Quality of Life Instrument (IBS-QOL) Questionnaire Scores: 2023 – Present



A condition-specific measure for assessing health-related QoL among persons with irritable bowel syndrome

Restem-L: Phase 2 Trial in Ulcerative Colitis (UC)

Adaptive double-blinded, randomized, parallel-group Induction and Treat-Through Maintenance study



Endpoints
Safety
Achievement of clinical response of disease in each group at the primary analysis timepoint: Week 14, following Induction.
Achievement of clinical response of disease in each group at the primary analysis timepoint: Week 52, following Maintenance.



Institution / Investigator:
Northwestern University Medical Center / Steve B. Hanauer, MD (Principal Investigator)

Diverse Clinical Indications - Restem-L

Indication	Participants	Doses
1. IIM / DM-PM (Phase 1)	9	9
2. LVAD (Phase 1)	9	9
3. COVID (Phase 1)	17	23
COVID (eINDs)	9	9
4. HLH, SL (eIND)	1	1
5. Graft v. Host, SG (eIND)	2	3
6. Pulmonary Fibrosis, GK (eIND)	1	4
7. Interstitial Lung Disease, BM (eIND)	1	1
8. Autoimmune Hep, TC (eIND)	1	6
9. Neuromyelitis Optica, KL (eIND)	1	1
10. Ulcerative Colitis, AC (eIND)	1	7
11. Crohn's Disease, JW (eIND)	1	3
TOTAL	54	76

Superb Clinical Safety Profile - Restem-L

Positive safety profile across different types of disease indications supports the potential for early additive or combination treatment opportunities

Adverse Reaction	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Infusion Reactions:					
Anaphylaxis	0	0	0	0	0
Chills	0	0	0	0	0
Skin Reaction	0	0	0	0	0
Hyper/Hypotension	0	0	0	0	0
Flushing	1	0	0	0	0
CNS Reactions:					
Fatigue	0	0	0	0	0
Confusion	0	0	0	0	0
Headache	0	0	0	0	0
Nausea	0	0	0	0	0
Cardiopulmonary Reactions	0	0	0	0	0
Gastrointestinal Reactions	0	0	0	0	0
Infection	0	0	0	0	0
Thromboembolic Events	0	0	0	0	0
TOTAL	1/76	0/76	0/76	0/76	0/76




(RESTEM

**Restem-X:
A Regenerative Secretome**

Restem-X — Revolutionizing Joint Regeneration and Repair

Natural Product with a Strong Orthopedic Therapeutic Potential

- Restem-X is a cell-based secretome derived from our proprietary Restem-L (UMPC) product
 - UMPCs are stimulated to secrete a functionally optimized profile of bioactive molecules which create an ideal formulation to collectively support joint health
- These bioactive molecules enhance cellular communication and promote tissue repair and regeneration
- RESTEM-X contains collagen I & III, hyaluronic acid (HA) and fibroblast growth factor-2 (FGF-2) & 7 (FGF-7) which are key components in tissue repair and overall joint health



Restem-X — Potential Disease Resolution vs Symptomatic Suppression

Osteoarthritis

Steroids & Visco-supplementation

Temporary pain relief with cartilage loss

Total Knee Replacement

STANDARD OF CARE

Decreases inflammation & provides structural support via extra cellular matrix

Long-term pain relief without cartilage loss

Improved Quality of Life


RESTEM-X

Restem-X — Future Price Competitiveness (per Treatment)

Visco-supplementation market valuation of \$5.12 B in 2024*




*<https://www.globenewswire.com/news-release/2025/01/06/3004788/0/en/Global-Viscosupplementation-Market-to-Hit-Valuation-US-11-31-Billion-By-2033-Astute-Analytica.html>
** Source LifeSci Consulting market analysis, 2025



(RESTEM

**Activated Natural Killer Cells:
Reducing the Burden of Senescent Cells**


Activated Natural Killer (aNK) Cells – Target Senescent Cells




- Our *activated* Natural Killer (aNK) cells are proprietary immune cells specifically enhanced to recognize and eliminate senescent cells which may reverse age-associated diseases
- Patented methods to isolate, purify, expand and activate NK cells
- Restem is only company harnessing the power of NK cells to target and reverse cellular senescence

Activated Natural Killer (aNK) Cells - Reduces Immunosenescence

Untreated Aging




Treated Aging




Effects of aNK on Senescence Biomarkers in Patients

aNK treatment significantly reduced key senescence markers (p16 and β -gal) in PBMCs isolated from donors



Significant reduction in p16 levels, post aNK treatment



Decrease in β -gal activity in all donors, post aNK treatment

These findings support the therapeutic potential of aNK in restoring immune function and targeting senescent cells in aging-associated diseases


Recent & Upcoming Milestones



	H2 2025	H1 2026	H2 2026
Restem-L	Initiated Phase 1/2a trial in FSHD	Received IND clearance for Phase 2/3 in RA & Phase 2 in UC Initiation of Phase 2/3 trial in IIM & Phase 2/3 in RA	Initiation of Phase 2 trial in UC Interim data for Phase 2/3 in IIM
Restem-X		IND submission for Phase 1/2 in OA	Initiation of Phase 1/2 trial in OA
aNK		IND submission for Phase 1 in age-associated disorder	Initiation of Phase 1 trial in age-associated disorder
Cash Runway into Q3 2028	Closed Friends&Family \$18M		
	Series A / Crossover Round \$50M-\$60M		
	Secured non-dilutive funding for IIM & FSHD Trials \$10.4M		

Thank You

(RESTEM



Thank You